

AMENDMENTS TO THE CLAIMS

Claims 1-7 (Canceled).

Claim 8 (Currently Amended): A method for increasing the cytostatic or cytotoxic effects on tumor cells, and decreasing the cytotoxic effect on normal leucocytes of an anticancer medicinal product comprising one or more platinum derivative selected among platinum derivatives, wherein said method comprises administering to a patient treated with said anticancer medicinal product, an antitumoral and leukocyte-protecting amount of mangafodipir and wherein said platinum derivative is cisplatin or oxaliplatin.

Claim 9 (Canceled)

Claim 10 (Previously Presented) The method of claim 8, wherein the amount of mangafodipir administered to said patient is from 1 to 100mg/kg/day.

Claim 11 (Currently Amended) A pharmaceutical composition comprising mangafodipir and an antitumor agent comprising one or more platinum derivative selected among platinum derivatives wherein said platinum derivative is cisplatin or oxaliplatin.